Stat3 mutations impact on overall survival in large granular lymphocyte leukemia: a single-center experience of 205 patients

Large granular lymphocyte leukemia (LGLL) is a rare and chronic lymphoproliferative disorder characterized by the clonal expansion of LGLs. LGLL patients can be asymptomatic or develop cytopenia, mostly neutropenia. Somatic STAT3 and STAT5b mutations have been recently reported in approximately 40%...

Full description

Saved in:
Bibliographic Details
Published in:Leukemia 2020-04, Vol.34 (4), p.1116-1124
Main Authors: Barilà, Gregorio, Teramo, Antonella, Calabretto, Giulia, Vicenzetto, Cristina, Gasparini, Vanessa Rebecca, Pavan, Laura, Leoncin, Matteo, Vedovato, Susanna, Frigo, Anna Chiara, Facco, Monica, Semenzato, Gianpietro, Zambello, Renato
Format: Article
Language:English
Subjects:
13/1
13/31
45/22
45/23
631/67/1990/291/1621
692/499
Adult
Aged
Aged, 80 and over
Asymptomatic
Biomarkers, Tumor - genetics
Cancer Research
Care and treatment
Critical Care Medicine
Development and progression
Female
Follow-Up Studies
Gene mutations
Genetic aspects
Health aspects
Hematology
Humans
Intensive
Internal Medicine
Leukemia
Leukemia, Large Granular Lymphocytic - genetics
Leukemia, Large Granular Lymphocytic - mortality
Leukemia, Large Granular Lymphocytic - pathology
Lymphocytes
Lymphocytic leukemia
Male
Medicine
Medicine & Public Health
Middle Aged
Multivariate analysis
Mutation
Neutropenia
Oncology
Patients
Prognosis
Retrospective Studies
Signal Transduction
Stat3 protein
STAT3 Transcription Factor - genetics
STAT5 Transcription Factor - genetics
Survival
Survival Rate
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Large granular lymphocyte leukemia (LGLL) is a rare and chronic lymphoproliferative disorder characterized by the clonal expansion of LGLs. LGLL patients can be asymptomatic or develop cytopenia, mostly neutropenia. Somatic STAT3 and STAT5b mutations have been recently reported in approximately 40% of patients. The aim of this study is to analyze clinical and biological features of a large cohort of LGLL patients to identify prognostic markers affecting patients’ outcome. In 205 LGLL patients, neutropenia (ANC 
ISSN:0887-6924
1476-5551
DOI:10.1038/s41375-019-0644-0